Nuvectis Pharma, Inc. reports developments as a clinical-stage biopharmaceutical company focused on precision medicines for serious oncology indications. Company news centers on NXP900, an oral small-molecule inhibitor of the SRC Family of Kinases, including SRC and YES1, and on clinical and preclinical work in genetically or molecularly defined cancer settings.
Recurring updates include financial results, business highlights, clinical program progress, AACR and other oncology conference presentations, pharmacokinetic and pharmacodynamic findings, drug-drug interaction data, and combination-therapy research in non-small cell lung cancer and other advanced solid tumors. News also covers capital resources and financing activity tied to development operations.
Nuvectis Pharma, Inc. (Nasdaq: NVCT) has successfully closed its upsized initial public offering, selling 3,200,000 shares at $5.00 each, raising gross proceeds of $16 million. The funds will support the Phase 1/2 development of NXP800, IND-enabling studies for NXP900, and general corporate purposes, including hiring and capital expenditures. H.C. Wainwright & Co. managed the offering. The related registration statements became effective on February 4, 2022. Nuvectis focuses on innovative precision medicines for oncology, with NXP800 currently in clinical trials and NXP900 in preclinical development.
Nuvectis Pharma, Inc. (Nasdaq: NVCT) has announced the pricing of its initial public offering (IPO) of 3,200,000 shares at $5.00 each, aiming for gross proceeds of $16 million. The underwriter, H.C. Wainwright & Co., has an option to purchase an additional 480,000 shares. Proceeds will be allocated to the Phase 1/2 development of NXP800, IND-enabling studies for NXP900, and other corporate needs. Trading on the Nasdaq begins today with the offering expected to close on February 8, 2022, subject to customary closing conditions.